Senzime Financial Statements From 2010 to 2024

SEZI Stock  SEK 5.76  0.08  1.37%   
Senzime AB financial statements provide useful quarterly and yearly information to potential Senzime AB investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Senzime AB financial statements helps investors assess Senzime AB's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Senzime AB's valuation are summarized below:
Senzime AB does not presently have any fundamental trend indicators for analysis.
Check Senzime AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senzime AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Senzime financial statements analysis is a perfect complement when working with Senzime AB Valuation or Volatility modules.
  
This module can also supplement various Senzime AB Technical models . Check out the analysis of Senzime AB Correlation against competitors.

Senzime AB Company Return On Equity Analysis

Senzime AB's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Senzime AB Return On Equity

    
  -0.64  
Most of Senzime AB's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Senzime AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Senzime AB has a Return On Equity of -0.6434. This is 97.32% lower than that of the Health Care Equipment & Supplies sector and 92.63% lower than that of the Health Care industry. The return on equity for all Sweden stocks is 107.55% higher than that of the company.

Senzime AB Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Senzime AB's current stock value. Our valuation model uses many indicators to compare Senzime AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Senzime AB competition to find correlations between indicators driving Senzime AB's intrinsic value. More Info.
Senzime AB is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Senzime AB's earnings, one of the primary drivers of an investment's value.

About Senzime AB Financial Statements

Senzime AB shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Senzime AB investors may analyze each financial statement separately, they are all interrelated. The changes in Senzime AB's assets and liabilities, for example, are also reflected in the revenues and expenses on on Senzime AB's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Senzime AB develops patient-oriented monitoring systems that assess patients biochemical and physiological processes before, during and after surgery in Sweden. Senzime AB was founded in 1997 and is based in Uppsala, Sweden. Senzime AB is traded on Stockholm Stock Exchange in Sweden.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Senzime Stock Analysis

When running Senzime AB's price analysis, check to measure Senzime AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senzime AB is operating at the current time. Most of Senzime AB's value examination focuses on studying past and present price action to predict the probability of Senzime AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senzime AB's price. Additionally, you may evaluate how the addition of Senzime AB to your portfolios can decrease your overall portfolio volatility.